ARC-201 / Araris Biotech - LARVOL DELTA

A novel dual-TOP1i ADC targeting NaPi2b designed for high efficacy and tolerability (AACR 2025) - "We here show promising efficacy and tolerability results on a noveldual-TOP1i ADC with optimized Exatecan bystander activity to maximize efficacy and manage Exatecan toxicity. We believe that this approach, in combination with a stable payload attachment at low DAR and an excellent exposure may help to develop ADCs with improved therapeutic indices for various solid tumor indications with the potential to become a best-in-class ADC."

Clinical • Late-breaking abstract • Oncology • Solid Tumor • SLC34A2

Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech (GlobeNewswire) - "Taiho Pharmaceutical...and Araris Biotech AG...announced today that they have entered into a definitive agreement pursuant to which Taiho Pharmaceutical will fully acquire Araris (hereinafter 'the Acquisition'). Following necessary procedures, the Acquisition is expected to be completed in first half of 2025. The Acquisition follows a research collaboration between Taiho Pharmaceutical and Araris signed in November 2023. Under the terms of the agreement, Taiho Pharmaceutical will pay USD 400 million at closing, with the potential for additional milestone payments of up to USD 740 million....Araris is advancing three products for the treatment of hematological and solid tumors developed using its unique AraLinQ technology, which are currently in the preclinical stage. These products are anticipated to enter into clinical trials between 2025 and 2026."

M&A • New trial • Hematological Malignancies • Oncology • Solid Tumor

Araris Biotech AG Presents Data on Novel Antibody-Drug Conjugates at American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) - "Araris Biotech AG...announced the company will deliver two poster presentations, including one late-breaking poster, at this year’s...AACR Annual Meeting....The presentations highlight preclinical data on two novel dual TOP1i antibody-drug conjugates (ADCs) generated using Araris’ proprietary ADC conjugation technology and linker platform....In mouse PK studies, the excellent in vitro stability of the ADC was confirmed with no signs of payload loss or linker-cleavage, and the ADC showed mAb-like exposure to maximize payload delivery. In head-to-head study vs T-DXd using a HER2-expressing breast cancer model, Araris’ ADC showed superior anti-tumor efficacy compared to T-DXd....Araris’ ADC demonstrated excellent and long-lasting anti-tumor potency in a single dose rodent study. Study demonstrated that generating an ADC that combines TOP1i payloads with two different features has the potential to overcome limitations of current clinical programs against NaPi2b."

Preclinical • Breast Cancer

Araris Biotech AG to Present Data on Antibody-Drug Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) - "Araris Biotech AG...today announced the company will be presenting one abstract and one late-breaking abstract during the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-10, 2024 at the San Diego Convention Center in San Diego, California."

Preclinical • Oncology • Solid Tumor